Smart High Tech publicerade den 11 maj 2023 bolagets delårsrapport för det första kvartalet 2023.
Lönsamheten förbättrades under Q1 och Elanders närmar sig sitt långsiktiga marginalmål.
Carlsquare Equity Research kommenterar delårsrapporten och de senaste nyheterna rörande Aberas proje...
Analyst Group har idag publicerat en analysartikel avseende Precise Biometrics.
Redeye notes a higher OPEX than expected in the company’s Q1 report.
Etteplan's net sales in Q1 amounted to EUR 95.0m, slightly above our and consensus estimates (EUR 92...
SmartCraft levererade ytterligare ett starkt kvartal med hög tillväxt.
Redeye updates its estimates following Freemelt’s Q1 report.
Redeye provides its comment on Ultimovacs’ Q1 2023 report, which featured no surprises.
Redeye maintains its positive view on Infracom following the Q1 2023 report, in which sales came in ...
Redeye provides its comment on Sprint Bioscience’s Q1 2023 report, and we judge that the company nee...
Redeye comments on Spago’s Q1 2023 report, and we judge the coming 2-3 months will provide some inte...
Redeye saw a Q1 report that was slightly weaker than expected but not a material deviation.
Redeye sees a strong Q1 report from Speqta with accelerating net customer intake, strengthening our ...
Redeye states that Truecaller delivered revenues below estimates, but that adjusted EBIDTA beat cons...
Redeye comments on Mestro’s Q1 2023 report and on the announced indicative public takeover offer in ...
Redeye comments on Tessin’s Q1 results, which showed solid growth despite a significant cost reducti...
Redeye states its view of Xavi Solutions’ Q1 2023 report, released earlier today.
Weaker EBIT partly due to lower than expected Öyfjellet contribution Project portfolio of ~24.
ITAB’s Q1 report was weak, with key retail clients remaining cautious and the company investing heav...
